| CRISPR Medicine | This is an overview of our news stories
Eli Lilly announced today that it will acquire Verve Therapeutics for up to $1.3 billion to develop single-dose base-editing treatments for people...
Chinese researchers have developed a thermosensitive, polyamine-modified hydrogel that significantly improves the co-delivery of CRISPR/Cas9 gene...
Some of the best links we picked up around the internet
SNIPR Biome has dosed the first patient in its Phase 1b trial of SNIPR001, a CRISPR-CAS-armed bacteriophage therapy that represents a new frontier in...
A new computational framework called CCLMoff uses deep learning and RNA language models to predict off-target effects in CRISPR-CAS9 genome editing...
Modalis Therapeutics has partnered with SOLVE FSHD to advance the development of an experimental epigenome-editing therapy for facioscapulohumeral...
Using CRISPR-Cas9 screens, researchers in the United States, Belgium and China have identified NR2F2 as a key driver of endocrine resistance in breast...
